Literature DB >> 9160859

Intracrine and autocrine effects of basic fibroblast growth factor in vascular smooth muscle cells.

M G Davis1, M Zhou, S Ali, J D Coffin, T Doetschman, G W Dorn.   

Abstract

In order to elucidate the effects of the different basic fibroblast growth factor (bFGF) isoforms on vascular smooth muscle, we examined aorta-derived vascular smooth muscle cells from transgenic mice expressing the human isoforms of bFGF. Four cell lines were examined from mice in which transgene expression was driven by the ubiquitous phosphoglycerate kinase promoter. Overexpression and cellular localization was confirmed by Western blot analysis in vascular smooth muscle cells from mice expressing: all four human bFGF isoforms (24, 22, 21, and 18 kDa); all three nuclear targeted isoforms (24, 22, and 21 kDa); only the 24 kDa isoform; and the only secreted/non-nuclear targeted isoform, 18 kDa. All lines showed approximate four-fold increases in bFGF expression, nuclear localization of all nuclear targeted bFGF isoforms, and cytosolic localization of only the 18 kDa bFGF. Measurement of [3H]thymidine incorporation into quiescent cells stimulated with increasing concentrations of serum, showed increased DNA synthesis in cell lines expressing any bFGF isoform when compared to non-transgenic control cells, and a further increase in DNA synthesis in cells expressing the nuclear targeted isoforms (24, 22, and 21 kDa) over the 18 kDa bFGF expressing cell line at any concentration of serum. All cells showed equal label incorporation when stimulated with 10 ng/ml of platelet-derived growth factor confirming an equal potential for DNA synthesis. Neutralizing the bFGF antibody markedly decreased serum-stimulated DNA synthesis, but only in the cell lines overexpressing the secreted/non-nuclear targeted 18 kDa isoform. These results suggest amplification of DNA synthesis through synergistic intracrine and autocrine effects of the nuclear targeted and non-nuclear targeted bFGF isoforms in vascular smooth muscle cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9160859     DOI: 10.1006/jmcc.1997.0383

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  17 in total

1.  Nuclear activities of basic fibroblast growth factor: potentiation of low-serum growth mediated by natural or chimeric nuclear localization signals.

Authors:  M Arese; Y Chen; R Z Florkiewicz; A Gualandris; B Shen; D B Rifkin
Journal:  Mol Biol Cell       Date:  1999-05       Impact factor: 4.138

2.  A serologically identified tumor antigen encoded by a homeobox gene promotes growth of ovarian epithelial cells.

Authors:  H Naora; Y Q Yang; F J Montz; J D Seidman; R J Kurman; R B Roden
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

3.  Fibroblast growth factor 2 control of vascular tone.

Authors:  M Zhou; R L Sutliff; R J Paul; J N Lorenz; J B Hoying; C C Haudenschild; M Yin; J D Coffin; L Kong; E G Kranias; W Luo; G P Boivin; J J Duffy; S A Pawlowski; T Doetschman
Journal:  Nat Med       Date:  1998-02       Impact factor: 53.440

4.  Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation.

Authors:  A Montero; Y Okada; M Tomita; M Ito; H Tsurukami; T Nakamura; T Doetschman; J D Coffin; M M Hurley
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

5.  The influence of FGF2 high molecular weight (HMW) isoforms in the development of cardiac ischemia-reperfusion injury.

Authors:  Siyun Liao; Janet R Bodmer; Mohamad Azhar; Gilbert Newman; J Douglas Coffin; Thomas Doetschman; Jo El J Schultz
Journal:  J Mol Cell Cardiol       Date:  2010-01-29       Impact factor: 5.000

6.  Production of basic fibroblast growth factor and interleukin 6 by human smooth muscle cells following infection with Chlamydia pneumoniae.

Authors:  J Rödel; M Woytas; A Groh; K H Schmidt; M Hartmann; M Lehmann; E Straube
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

7.  Impaired cerebral cortex development and blood pressure regulation in FGF-2-deficient mice.

Authors:  R Dono; G Texido; R Dussel; H Ehmke; R Zeller
Journal:  EMBO J       Date:  1998-08-03       Impact factor: 11.598

Review 8.  Transforming growth factor beta in cardiovascular development and function.

Authors:  Mohamad Azhar; Jo El J Schultz; Ingrid Grupp; Gerald W Dorn; Pierre Meneton; Daniel G M Molin; Adriana C Gittenberger-de Groot; Thomas Doetschman
Journal:  Cytokine Growth Factor Rev       Date:  2003-10       Impact factor: 7.638

9.  A new 34-kilodalton isoform of human fibroblast growth factor 2 is cap dependently synthesized by using a non-AUG start codon and behaves as a survival factor.

Authors:  E Arnaud; C Touriol; C Boutonnet; M C Gensac; S Vagner; H Prats; A C Prats
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

10.  Gene targeted ablation of high molecular weight fibroblast growth factor-2.

Authors:  Mohamad Azhar; Moying Yin; Ming Zhou; Hongqi Li; Marwan Mustafa; Eyad Nusayr; Jack B Keenan; Hwudaurw Chen; Sharon Pawlosky; Connie Gard; Christina Grisham; L Philip Sanford; Tom Doetschman
Journal:  Dev Dyn       Date:  2009-02       Impact factor: 3.780

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.